Kerry Mahon, Ph.D.

Executive Director, Innovation and Corporate Business Development

Kerry is driven to build companies that accelerate the development of new technologies with the potential to transform human health. At Valo, Kerry’s responsibilities cover all aspects of strategic partnering, including collaborations, licensing, M&A, and new entity formation. Having joined the company in 2020, he has over fifteen years of experience in working in the industries of biotech, healthtech, and pharmaceuticals, ranging from startups to Fortune 100 companies.

Prior to Valo, Kerry spent five years at Verily, operating at the intersection of healthcare technology and data science to lead transactions across medical device, life science, and clinical data initiatives. Before Verily, Kerry was part of the deal team at Depomed, focused on partnering late-stage and commercial assets in pain and neurology. Kerry started his career in product development at Stemgent, where he developed his own academic discoveries into the first commercially available products related to mRNA for iPSC generation before transitioning to business development. He also advises early-stage biotechnology companies and had an early career stint in process development at Pfizer.

Kerry holds a B.A. in Chemistry from the College of the Holy Cross, a Ph.D. in Chemistry from Boston College, and did his Postdoctoral Fellowship at MIT, with multiple publications and patents to his name.